Table.

Cox proportional hazards regression models of prostate cancer progression risk during followup using patient characteristics available at surveillance biopsy 1

Variables*	No. Progression/No. Subgroup Pts	Univariate		Multivariate 1		Multivariate 2
		Adjusted HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Age at biopsy:			0.006		0.173		0.109
Less than 70	55/220	1 (referent)		1 (referent)		1 (referent)
70 or Greater	18/47	2.1 (1.3, 3.7)		1.6 (0.8, 3.0)		1.7 (0.9, 3.2)
PSA at biopsy (ng/ml):			0.013		0.369		0.305
Less than 3.0	11/81	1 (referent)		1 (referent)		1 (referent)
3.0 or Greater	62/186	2.3 (1.2, 4.3)		1.5 (0.6, 3.5)		1.6 (0.7, 3.6)
PSA density (ng/ml/cm3):			<0.001		0.016		0.040
Less than 0.08	24/135	1 (referent)		1 (referent)		1 (referent)
0.08 or Greater	46/114	2.5 (1.5, 4.1)		2.2 (1.2, 4.2)		1.9 (1.0, 3.5)
% PSA at diagnosis:			0.040		0.395		0.316
Greater than 15	46/190	1 (referent)		1 (referent)		1 (referent)
15 or Less	20/52	1.7 (1.0, 2.9)		1.3 (0.7, 2.3)		1.3 (0.8, 2.3)
Max % core Ca involvement:			<0.001		<0.001
Less than 5	42/212	1 (referent)		1 (referent)
5 or Greater	31/54	3.7 (2.3, 5.8)		3.4 (2.1, 5.7)
Initial surveillance biopsy result:			<0.001				<0.001
Neg	21/152	1 (referent)				1 (referent)
Pos	52/115	3.8 (2.3, 6.2)				3.5 (2.0, 6.0)

^*In 226 men with at least 2 followup biopsies after the diagnostic biopsy, including 64 with and 162 without unfavorable biopsy result at the first surveillance biopsy, with followup defined as the date of initial surveillance biopsy to the date of unfavorable biopsy or the last favorable biopsy in censored patients, and with censoring of those who were lost to followup, withdrew or had died by the last biopsy date.